AstraZeneca, Britain’s second-largest pharmaceutical company, is planning to outsource all its drug manufacturing activities within ten years.
David Smith, AstraZeneca’s executive vice-president of operations, said that the company aimed to become a pure research, development and marketing organisation.
“Manufacturing for AstraZeneca is not a core activity,” Mr Smith said. “AstraZeneca is about innovation and brand-building . . . There are lots of people and organisations that can manufacture better than we can.”
More at The Times .
But Insider would suggest that, given your recent track record with Exanta and Crestor (to name but two), you're not that hot at innovation or brand-building either!